This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2010 May 27;115(21):4316-7; author reply 4317.

doi: 10.1182/blood-2010-01-265728.

Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting

Mohamed A Kharfan-Dabaja, Joseph Pidala, Claudio Anasetti

PMID: 20508174
PMCID: PMC3374378
DOI: 10.1182/blood-2010-01-265728

Clinical Trial

Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting

Mohamed A Kharfan-Dabaja et al. Blood. 2010.

. 2010 May 27;115(21):4316-7; author reply 4317.

doi: 10.1182/blood-2010-01-265728.

Authors

Mohamed A Kharfan-Dabaja, Joseph Pidala, Claudio Anasetti

PMID: 20508174
PMCID: PMC3374378
DOI: 10.1182/blood-2010-01-265728

No abstract available

PubMed Disclaimer

Comment on

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. Rodriguez R, et al. Blood. 2010 Feb 4;115(5):1098-105. doi: 10.1182/blood-2009-03-207563. Epub 2009 Nov 19. Blood. 2010. PMID: 19965688 Free PMC article. Clinical Trial.

Similar articles

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, Díez-Campelo M, Sánchez-Guijo F, Pérez-López E, Guerrero C, Alberca I, Del Cañizo MC, Pérez-Simón JA, González-Porras JR, Caballero D. Labrador J, et al. Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24. Bone Marrow Transplant. 2014. PMID: 24566710
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. Rodriguez R, et al. Blood. 2010 Feb 4;115(5):1098-105. doi: 10.1182/blood-2009-03-207563. Epub 2009 Nov 19. Blood. 2010. PMID: 19965688 Free PMC article. Clinical Trial.
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T, Parker PM, Khaled SK, Forman SJ, Nakamura R. Shayani S, et al. Biol Blood Marrow Transplant. 2013 Feb;19(2):298-304. doi: 10.1016/j.bbmt.2012.10.006. Epub 2012 Oct 15. Biol Blood Marrow Transplant. 2013. PMID: 23078784 Free PMC article.
Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
Cutler C, Antin JH. Cutler C, et al. Curr Opin Hematol. 2010 Nov;17(6):500-4. doi: 10.1097/MOH.0b013e32833e5b2e. Curr Opin Hematol. 2010. PMID: 20717025 Review.
The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.
Wang L, Gu Z, Zhai R, Li D, Zhao S, Luo L, Zhao X, Wei H, Pang Z, Wang L, Liu D, Wang Q, Gao C. Wang L, et al. Transfusion. 2015 Sep;55(9):2134-41. doi: 10.1111/trf.13110. Epub 2015 Apr 9. Transfusion. 2015. PMID: 25857725 Review.

See all similar articles

Cited by

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, Díez-Campelo M, Sánchez-Guijo F, Pérez-López E, Guerrero C, Alberca I, Del Cañizo MC, Pérez-Simón JA, González-Porras JR, Caballero D. Labrador J, et al. Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24. Bone Marrow Transplant. 2014. PMID: 24566710
The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Balassa K, Andrikovics H, Remenyi P, Batai A, Bors A, Kiss KP, Szilvasi A, Rajczy K, Inotai D, Gopcsa L, Lengyel L, Barta A, Reti M, Tordai A, Masszi T. Balassa K, et al. Bone Marrow Transplant. 2015 Oct;50(10):1321-5. doi: 10.1038/bmt.2015.161. Epub 2015 Jul 6. Bone Marrow Transplant. 2015. PMID: 26146809

References

1. Khuu T, Shayani S, Palmer J, et al. Thrombotic microangiopathy with tacrolimus/sirolimus-based GVHD prophylaxis regimen in patients undergoing hematopoietic stem cell transplant from a matched unrelated donor [abstract]. Blood. 2008;112(11) Abstract 797.
1. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098–1105. - PMC - PubMed
1. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112(12):4425–4431. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal